Summary
1675 breast cancer patients in the Auckland regional area have been divided into two major groups according to delay in diagnosis greater or less than six weeks. Overall there is no difference in survival although the variables tumour size, skin attachment, and nipple retraction are more common in the group with longer delay, and grade III tumours in those with short delay. Three important prognostic variables (the presence of tumour steroid receptors, positive axillary nodes, and distant metastases at diagnosis) are equally distributed and have a similar effect on survival within the two delay groups. However, in a subgroup of women with negative axillary nodes, short delay is associated with poorer survival, independent of tumour size. More tumours with grade III histology and a negative progesterone receptor status are found in this subgroup. Thus, short delay may constitute a new prognostic variable of some importance when in association with negative axillary nodes.
References
Elwood JM, Moorehead WP: Delay in diagnosis and longterm survival in breast cancer. Br Med J 280: 1291–1294, 1980
Fisher ER, Redmond C, Fisher B: A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer 40: 3160–3167, 1977
Sheridan B, Fleming J, Atkinson L, Scott G: The effects of delay in treatment on survival rates in carcinoma of the breast. The Med J of Aust 1: 262–267, 1971
Greer S, Morris T: Psychological attributes of women who develop breast cancer: a controlled study. J Psychom Res 19: 153, 1975
Magarey CJ, Todd PB, Blizard PJ: Psycho-social factors influencing delay and breast self examination in women with symptoms of breast cancer. Soc Science & Med 11: 229–232, 1977
MacArthur C, Smith A: Delay in breast cancer and the nature of presenting symptoms. Lancet 1: 601–603, 1981
Shapiro S, Venet W, Strax P, Venet L, Roeser R: Ten to fourteen year effects of breast cancer screening on mortality. J Natl Cancer Inst 69: 349–355, 1982
Tabar L, Gad A: Screening for breast cancer — the Swedish trial. Radiology 138: 219–222, 1981
Collette H, Day N, Rombach J, de Waard F: Evaluation of screening for breast cancer in a non-randomized study (the DOM project) by means of a case-control study. Lancet 1: 1224–1226, 1984
Cutler S: The prognosis of treated breast cancer. In: Forrest A, Kunkler P (eds) Prognostic factors in breast cancer. Edinburgh, 1968, pp 20–31
Mason B, Holdaway I, Mullins P, Yee L, Kay R: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985–2990, 1983
Bloom HJ, Richardson W, Harries E: Natural history of untreated breast cancer (1805–1933) — comparison of untreated cases according to histiological grade of malignancy. Br Med J 2: 213–221, 1962
Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377, 1957
Holdaway IM, Mountjoy KG: Progesterone and oestrogen receptors in human breast cancer. Aust NZ J Med 8: 630–638, 1978
Harrell FE: In: Cary NC: SAS Institute Inc Supplemental Users Guide; SAS Institute Inc. 1983, pp 267–274
De Groote R, Rush BF, Milazzo J, Warden MJ, Rocko JM: Interval breast cancer: A more aggressive subset of breast neoplasms. Surgery 94: 4 543–547, 1983
Dennis CR, Gardner B, Lim B: Analysis of survival and recurrence vs patient and doctor delay in treatment of breast cancer. Cancer 35: 714–720, 1975
Bloom HJ: Further studies on prognosis of breast carcinoma. Br J Cancer 4: 347–367, 1950
Cutler SJ, Myers MH, White PL: Who are we missing and why? Cancer 37: 421–425, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neave, L.M., Mason, B.H. & Kay, R.G. Does delay in diagnosis of breast cancer affect survival?. Breast Cancer Res Tr 15, 103–108 (1990). https://doi.org/10.1007/BF01810782
Issue Date:
DOI: https://doi.org/10.1007/BF01810782